Back
#1
15.6%
Top 2%
12.6%
Top 7%
11.7%
Top 0.7%
10.0%
Top 64%
8.3%
Top 63%
4.1%
Top 2%
3.0%
Top 6%
3.0%
Top 3%
2.1%
Top 19%
2.1%
Top 2%
2.1%
Top 56%
1.4%
Top 12%
1.3%
Top 4%
1.0%
Top 6%
0.8%
Top 13%
0.8%
Top 6%
0.8%
Top 6%
0.8%
Top 2%
0.8%
Top 5%
0.8%
Top 12%
0.8%
A first-in-human, Phase 1/2a, open-label study of SQ3370, a first-in-class doxorubicin-based click chemistry therapeutic, in patients with advanced solid tumors
2025-06-03
oncology
Title + abstract only
View on medRxiv
Show abstract
BackgroundWe present the first clinical proof of concept using click chemistry to selectively capture drugs at tumors. SQ3370 combines a clickable pre-targeting agent (intratumorally injected biopolymer, SQL70) and a chemically-attenuated doxorubicin (Dox) protodrug (SQP33) that is activated upon clicking with the biopolymer at the tumor to rapidly release high local concentrations of native doxorubicin. MethodsThis was a Phase 1/2a open-label study in patients with advanced solid tumors (NCT04...
Predicted journal destinations
1
Clinical Cancer Research
22 training papers
2
Cancers
57 training papers
3
Nature Communications
483 training papers
4
Frontiers in Oncology
34 training papers
5
PLOS ONE
1737 training papers
6
Scientific Reports
701 training papers
7
Cancer Medicine
17 training papers
8
JAMA Network Open
125 training papers
9
British Journal of Cancer
22 training papers
10
eLife
262 training papers
11
BMC Cancer
21 training papers
12
BMJ Open
553 training papers
13
Proceedings of the National Academy of Sciences
100 training papers
14
Journal of Clinical Investigation
50 training papers
15
International Journal of Molecular Sciences
39 training papers
16
Frontiers in Immunology
140 training papers
17
Communications Medicine
63 training papers
18
Cell Reports Medicine
49 training papers
19
Cell Reports
25 training papers
20
Diagnostics
36 training papers
21
iScience
74 training papers